In addition to BRCA1 and BRCA2, several other susceptibility genes have been associated with BC, including TP53, PALB2, CHEK2, ATM and so on (Foulkes, 2021), indicating that the utilization of multi-gene panel testing could potentially confer enhanced benefits to patients (Bono et al., 2021). This evidence concerns the gene ATM and breast cancer.